Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635090 | 0.86 | BRD4 (0.44) | SLC7A5LOXL2 | |
| SCHEMBL4391966 | 0.82 | LOXL2 (0.58) | SLC7A5LOXL2MRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL9494583 | 0.80 | SLC7A5 (0.44) | SLC7A5ALDH1A1TSHR | |
| SCHEMBL4399149 | 0.79 | MRGPRX4 (0.50) | SLC7A5MRGPRX4RAB9ANPC1ALDH1A1 | |
| SCHEMBL16316860 | 0.78 | LOXL2 (0.44) | SLC7A5LOXL2GSK3BCYP4F2CYP4A11 | |
| SCHEMBL32665365 | 0.76 | NQO2 (0.44) | SLC7A5RAB9ANPC1KDM4EMAPT | |
| SCHEMBL17742315 | 0.76 | F2 (0.41) | ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL19658173 | 0.75 | KMT2A (0.44) | LOXL2GSK3BCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL16426741 | 0.75 | LOXL2 (0.40) | SLC7A5LOXL2GSK3BCYP4F2CYP4A11 | |
| SCHEMBL21939481 | 0.74 | CA12 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986694-B1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTHCARE AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | SLC7A5 1571/4885LOXL2 3513/4885MRGPRX4 1044/4885 |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | PTMS, VIP, LNPEP | SLC7A5 1571/4885LOXL2 3513/4885MRGPRX4 1044/4885 |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | GHRHR, GHITM, HDGF | SLC7A5 1160/4885LOXL2 3549/4885MRGPRX4 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.